生物降解材料复合成骨因子在骨科应用研究中的进展

doi:10.3969/j.issn.2095-4344.2015.52.021

摘要/Abstract

摘要：

背景：生物可降解植入物不仅可重建骨缺损部位，而且随着材料的逐步降解，新生骨组织可完全替代移植材料，填充骨缺损处。

目的：总结生物降解材料复合成骨因子在骨科的研究进展。

方法：以“可降解材料，成骨因子，细胞活性因子，骨组织工程；Biodegradable materials，factors，cell active factor，bone tissue engineering”为检索词，应用计算机检索PubMed、万方、CNKI数据库2000至2015年的相关文献。

结果与结论：生物可降解医用高分子材料可分为天然高分子材料和人工合成可降解材料。天然高分子材料具有良好的生物相容性，但其机械强度较差；人工合成可降解材料械强度较天然高分子材料高，但容易造成局部酸性物质堆积，产生局部炎症反应。将生物可降解医用高分子材料与成骨因子复合，可提高材料的力学强度与骨诱导能力，但将其作为骨修复材料应用于临床还有很多问题需要解决。

中国组织工程研究杂志出版内容重点：生物材料；骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性；组织工程

关键词: 生物材料, 骨生物材料, 生物降解材料, 成骨因子, 降解, 修复

Abstract:

BACKGROUND: Biodegradable implants cannot only rebuild bone defect site, moreover, with the gradual degradation of the materials, new bone tissue can completely replace the graft materials to fill bone defects.

OBJECTIVE: To summarize the research progress of biodegradable materials combined with osteogenic factor in orthopedics.

METHODS: We took the “biodegradable materials, factors, cell active factor, bone tissue engineering” as the search terms in Chinese and English, respectively, to retrieve the related literatures from PubMed, Wanfang and CNKI database during 2000 to 2015 by computer.

RESULTS AND CONCLUSION: Biodegradable medical polymer materials can be divided into natural polymer materials and synthetic biodegradable materials. Natural polymeric materials have good biocompatibility, but poor mechanical strength. The mechanical strength of synthetic biodegradable materials is higher than that of natural polymer materials, but the synthetic biodegradable materials are likely to cause local accumulation of acidic substances, produce local inflammation. The biodegradable medical polymer materials combined with osteogenic factor can improve the mechanical strength and osteoinductive ability of materials, but as a bone repair material, it still has many problems to be solved.

中国组织工程研究杂志出版内容重点：生物材料；骨生物材料; 口腔生物材料; 纳米材料; 缓释材料; 材料相容性；组织工程

中图分类号:

R318

刘大海，李开南，魏友华. 生物降解材料复合成骨因子在骨科应用研究中的进展[J]. 中国组织工程研究, 2015, 19(52): 8480-8486.

Liu Da-hai, Li Kai-nan, Wei You-hua. Biodegradable materials combined with osteogenic factor in orthopaedics [J]. Chinese Journal of Tissue Engineering Research, 2015, 19(52): 8480-8486.

参考文献

[1] Musgrave DS,Fu FH,Huard J.Gene therapy and tissue engineering in orthopaedic surgery.J Am Acad Orthop Surg. 2002;10(1):6-15.
[2] Salgado AJ,Coutinho OP,Reis RL.Bone tissue engineering: state of the art and future trends.Macromol Biosci. 2004; 4(8): 743-765.
[3] Middleton JC,Tipton AJ.Synthetic biodegradable polymers as orthopedic devices.Biomaterials.2000;21(23):2335-2346.
[4] 胡玲珑,李海,赵黎.壳聚糖作为辅助成分在骨组织工程研究中的应用[J].国际骨科学杂志,2012,33(6):395-397.
[5] Nagahama H,Rani VV,Shalumon KT, et al. Preparation, characterization, bioactive and cell attachment studies of alpha-chitin/gelatin composite menbranes.Int J Biol Macromol. 2009;44(4):333-337.
[6] Fakhry A,Schneider GB,Zaharias R,ct al.Chitosan supports the initial attachment and spreading of osteoblasts preferentially over fibroblasts. Biomaterials. 2004; 25(11): 2075-2079.
[7] Kiang T,Wen J,Lim HW,Leong KW.The effect of the degree of chitosan deacetylation on the efficiency of gene transfection. Biomaterials.2004;25(5):293-301.
[8] Hsu SH,Whu SW,Hsieh SC,et al.Evaluation of chitosan- alginate-hyaluronate complexes modified by an RGD-containing protein as tissue-engineerring scaffolds for cartilage regeneration.Artif Organs.2004;28(8):693-703.
[9] Zujur D,Moret J,Rodriguez D,et al.A novel photocrosslinkable and cytocompatible chitosan coating for Ti6Al4V surfaces.J Appl Biomater Funct Mater.2015;12(10):530-538.
[10] Malafaya PB,Silva GA,Reis RL.Natural-origin polymers as carriers and scaffolds for biomolecules and cell delivery in tissue engineering applications. Adv Drug Deliv Rev. 2007; 59(4-5):207-233.
[11] Jiang T,Nukavarapu SP,Deng M, et al. Chitosan-poly (lactide-co-glycolide) microsphere-based scaffolds for bone tissue engineering:in vitro degradation and in vivo bone regeneration studies.Acta Biomater.2010;6(9):3457-3470.
[12] Prabaharan M.Review paper:chitosan derivatives as promising materials for controlled drug delivery.J Biomater Appl.2008;23(1):5-36.
[13] Freier T,KOh HS,Kazazian K,et al.Controlling cell adhesion and degradation of chitosan films by N-acctylation. Biomaterials. 2005;26(29):5872-5878.
[14] Serra IR,Fradique R,Vallejo MC,et al.Production and characterization of chitosan/ gelatin/β-TCP scaffolds for improved bone tissue regener ation. Mater Sci Eng C Mater Biol Appl.2015;55(10):592-604.
[15] 杨志明,余希杰,黄富国,等.外源性Ⅰ型胶原对人胚骨膜成骨细胞生物学特性的影响[J].华西医科大学学报,2001,32(1):1-4.
[16] 王娅,冯扬.纤维蛋白凝胶在组织工程中的应用[J].国际口腔医学杂志,2008,35(S1):31-33.
[17] 姚琦,张立波,黄鹏,等.纤维蛋白胶复合重组人骨形态发生蛋白2微球的制备及评[J].中国组织工程研究与临床康复,2009,13(51): 10028-10032.
[18] 刘潇,李彦锋,崔彦君,等.脂肪族聚酯类可生物降解医用高分子材料的研究进展[J].化学通报,2010,77(4):220-226.
[19] 李开南,刘建峰,汪学军,等.可生物降解聚-DL-乳酸腰椎间融合器的设计及生物力学研究[J].中国脊柱脊髓杂志,2007,17(1): 38-41.
[20] 姚豹,李开南,聂海.可生物降解聚乳酸-乙醇酸共聚物腰椎横突间融合器的体内生物力学[J].中国组织工程研究, 2014,18(52): 8426-8432.
[21] Kido HW,Brassolatti P.Porous poly(D,L-lactide-co glycolide) acid/biosilicate composite scaffolds for bone tissue engineering.J Biomed Mater Res B Appl Biomater. 2015;9(28): 31-39.
[22] 陈廖斌,汪晖,商亮.聚酸酐药物控释系统在骨科的研究与应用[J].临床外科杂志,2004,12(12):774-776.
[23] Anseth KS,Shastri VR,Langer R.Photopolymerizable degradable polyanhydrides with osteocompatibility.Nat Biotechnol.1999;17(2):156-159.
[24] Díaz A,Katsarava R,Puiggalí J.Synthesis, properties and applications of biodegradable polymers derived from diols and dicarboxylic acids: from polyesters to poly(ester amide)s. Int J Mol Sci.2014;15(5):7064-7123.
[25] Chang KY,Cheng LW,Ho GH,et al.Fabrication and characterization of poly(γ-glutamic acid)-graft-chondroitin sulfate/polycaprolactone porous scaffolds for cartilage tissue engineering.Acta Biomaterialia.2009;5(6):1937-1947.
[26] Lavery K,Swain P,Falb D,et al.BMP-2/4 and BMP-6/7 differentially utilize cell surface receptors to induce osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells. Biol Chem. 2008;283(30):20948- 20958.
[27] Biver E,Soubrier AS,Thouverey C,et al.Fibroblast growth factor 2 inhibits up- regulation of bone morphogenic proteins and their receptors during osteoblastic differentiation of human mesenchymal stem cells. Biochem Biophys Res Commun.2012;427(4):737-742.
[28] Kubler N,Urist MR.Cell differentiation in response to partially purified osteosarcoma-derived bone morphogenetic protein in vivo and in vitro.Clin rothop.2003;29(2):321-328.
[29] 韩昕光,王东奎,高峰,等.骨不连断端及周围组织骨形态发生蛋白2与核心蛋白多糖的表达[J].中国组织工程研究, 2012,16(48): 9044-9049.
[30] Hasegawa Y.Roles of inhibins, activins and related proteins in reproduction. Nihon Rinsho.2006;21(4):277-283.
[31] Pepene CE,Seck T,Diel I,et al.Influence of fluor salts, hormone replacement therapy and calcitonin on the concentration of insulin-like growth factor (IGF)-I, IGF-II and transforming growth factor-beta 1 in human iliac crest bone matrix from patients with primary osteoporosis.Eur J Endocrinol. 2004;150(1):81-91.
[32] Marie PJ,Debiais F,Haÿ E. Regulation of human cranial osteoblast phenotype by FGF-2, FGFR-2 and BMP-2 signaling.Histol Histopathol.2002;17(3):877-885.
[33] Horner A,Bord S,Kenp P,et al.Distribution of platelet derived growth act or(PDGF)A chain mRNA,protein,and PDGF alpha receptor in rapidly forming human bone. Bone. 1996;19(4): 353-362.
[34] 徐亚青,姜小华,吴叶,PDGF在大鼠股骨干骨折愈合过程中的表达[J].中国骨肿瘤骨病,2011,10(1):46-49.
[35] Fronun SJ,Wallale S,Tarnow D.Effect of platelet-rich plasma on bone growth.Int J Periondonties Restorative Dent. 2002; 22(1):45-53.
[36] Ryan AM,Eppler DB,Hagler KE,et al. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody.Toxicol Pathol.2009;27(1):78-86.
[37] Street J,Bao M,deGuzman L,et al.Vascular endothel growth factor stimulates bone repair by promoting angiogenesis and bone turnover.Proc Nat Acad Sci USA. 2002;99(15):9656-9661.
[38] Kleinheinz J,Stratmann U,Joos U,et al.VEGF-activated angiogenesis druing bone regeneration.J Oral Maxillofac Surg.2005;63(9):1310-1316.
[39] Clarke SA,Hoskins NL,Jordan GR,et al.Healing of an ulnar defect using a proprietary TCP bone graft substitute,JAX,in association with autologous osteogenic cells and growth factors.Bone.2007;40(4):939-947.
[40] Kempen nDH,Lu L,Heijink A,et al.Effect of local sequential VEGF and BMP-2 delivery on ectopic and orthotopic bone regeneration.Biomaterials.2009;30(14):2816-2825.
[41] 张莉莉,李玉坤.生长因子对骨代谢影响的研究进展[J].国际药学研究杂志,2012,39(2):121-126.
[42] 石长贵,蔡筑韵,鲍哲明,等.骨生长因子促进骨折愈合研究进展[J].国际骨科学杂志,2010,31(3): 184-186.
[43] Szpalski C,Nguyen PD,Cretiu Vasiliu CE,et al.Bony Engineering Using Time-Release Porous Scaffolds to Provide Sustained Growth Factor Delivery.J Craniofac Surg. 2012; 23(3):638-644.
[44] Ward BB,Brown SE,Krebsbach PH.Bioengineering strategies for regeneration of craniofacial bone: a review of emerging technologies.Oral Dis.2010;16(8):709-716.
[45] 李夏林.仿生控释BMP-2和BMP-7的PELA微球支架的研制及其修复大鼠骨缺损的实验研究[D].广州:南方医科大学,2014.
[46] Rainche AT,PULEO DA.In vitro effects of combined and sequential delivery of two bone growth factors. Biomaterials. 2004;25(4):677-685.
[47] Meinel L,Zoidis E,Zapf J,et al.Localized insulin-like growth factor I delivery to enhance new bone formation. Bone. 2003; 33(4):660-672.
[48] Jiang T,Khan Y,Nair LS,et al.Functionalization of chitosan/poly (lactic acid-glycolic acid)sintered microsphere scaffolds via surface heparinization for bone tissue engineering.J Biomed Mater Res A.2010;93(3):1193-1208.
[49] 陈发明,吴织芬,金岩.生长因子载体及缓释系统的研究进展[J].国际口腔医学杂志,2005,32(1):44-46.
[50] 王玮,徐达传.RhBMP-2壳聚糖纳米微球及复合人工骨的制备和成骨活性研究[D].广州:南方医科大学,2011.
[51] 陈佳滨,武成聪,李强.转基因技术及骨髓间充质干细胞在骨缺损修复中的应用与展望[J].临床医学工程,2013,20(11):1457-1459.
[52] 向慧,覃佳强.BMP-9基因转染羊骨髓间充质干细胞的实验研究及其修复同种异体羊大段骨缺损的初步研究[D].重庆:重庆医科大学,2010.
[53] 费志强,沈慧勇,王大平.BMP-2基因修饰的骨髓间充质干细胞复合PLLA/n-HA人工骨修复大鼠股骨缺损的实验研究[D].广州:中山医科大学,2013.
[54] 岑超德,罗聪.可降解组织工程骨材料及其血管化研究：问题与应用前景[J].中国组织工程研究,2014,18(21):3391-3397.
[55] Roohani-Esfahani SI,Nouri-Khorasani S,Lu Z,et al.The influence hydroxyapatite nanoparticle shape and size on the properties of biphasic caicium phosphate scaffolds coated with hydroxyapatite-PCL composites. Biomaterials. 2010; 31(21):5498-5509.